Oral Squamous Cell CarcinomaSYMILIS OCTNCT06321003
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
An observational study of Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorder, run by University of Palermo at 1 site in Italy.
Trial summary
This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma (OSCC). Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder, Oral Leukoplakia
- What is being tested?
- OCT (Optical Coherence Tomography)
- Type of treatment
- Pill or oral medicine, Medical device
- How many people
- 200 participants
- Where
- 1 siteItaly
- Study dates
- 13 Mar 2024to 1 Apr 2028
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will be enrolled at the Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.) and at the Oral Medicine Clinic of the A.O.U.P. 'Paolo Giaccone' of Palermo, which serves as a primary care clinic. This includes patients visiting the clinic for either their initial consultation or follow-up appointments.
Who may be able to join
- Adult patients with clinical suspicion of potentially malignant oral disorders (OPMDs) and oral squamous cell carcinoma (OSCC).
- Patients able to provide informed consent for participation in the study.
- Availability of complete clinical data and medical records.
Who cannot join
- Patients with a previous diagnosis of OSCC/OPMDs and/or who have already undergone treatment.
- Patients with contraindications to the OCT examination for nonpermissive oral localization using the probe.
- Pregnant or breastfeeding women.
- Patients with disabilities, reluctance or difficulties of understanding to follow the procedures of the study and who have not provided a consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
University of Palermo
Palermo
091 238 93011, pec@cert.unipa.it
About this study
Official title: Single-blind Clinical Trial Assessing the Validity of Optical Coherence Tomography (OCT) in Diagnosing Potentially Malignant Oral Lesions and Oral Cancer
This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma (OSCC). Despite the availability of oral screening, diagnostic delays persist, underscoring the importance of exploring non-invasive methodologies. The OCT technology provides cross-sectional analysis of biological tissues, enabling a detailed evaluation of ultrastructural oral mucosal features.
The trial aims to compare OCT preliminary evaluation with traditional histology, considered the gold standard in oral lesion diagnosing. It seeks to create a database of pathological OCT data, facilitating the non invasive identification of carcinogenic processes. The goal is to develop a diagnostic algorithm based on OCT, enhancing its ability to detect characteristic patterns such as the keratinized layer, squamous epithelium, basement membrane, and lamina propria in oral tissues affected by OPMDs and OSCC.
Read more
Furthermore, the trial aims to implement Artificial Intelligence (AI) in OCT image analysis. The use of machine learning algorithms could contribute to a faster and more accurate assessment of images, aiding in early diagnosis. The trial aims to standardize the comparison between in vivo OCT images and histological analysis, adopting a site-specific approach in biopsies to improve correspondence between data collected by both methods.
In summary, the trial not only evaluates OCT as a diagnostic tool but also aims to integrate AI to develop a standardized approach that enhances the accuracy of oral cancer diagnosis, providing a significant contribution to clinical practice.
Read the detailed description
Background and needs:
Despite advancements in oral screening techniques, diagnostic delays persist, necessitating the exploration of non-invasive methodologies for early detection of oral cancer. The current standard diagnostic method, histological analysis, often requires invasive biopsies and can be time-consuming, leading to delays in treatment initiation. Moreover, traditional screening methods may not always detect early-stage oral lesions accurately. Therefore, there is a critical need to enhance diagnostic capabilities through the adoption of innovative technologies.
In this context, Optical Coherence Tomography (OCT) emerges as a promising technology warranting investigation. OCT offers several advantages over conventional diagnostic approaches. Its non-invasive nature allows for real-time and non-invasive imaging of tissue morphology with high resolution, enabling clinicians to visualize structural changes in oral tissues. By providing cross-sectional images of tissue layers, OCT has the potential to identify subtle alterations indicative of early-stage oral lesions, including potentially malignant disorders (OPMDs) and squamous cell carcinoma (OSCC). Additionally, OCT can facilitate early detection by enabling repeated examinations over time, thereby monitoring lesion progression or regression without the need for repeated biopsies.
The exploration of OCT as a diagnostic tool aligns with the urgent need to improve the efficiency and accuracy of oral cancer diagnosis. By leveraging the capabilities of OCT, clinicians can potentially expedite the identification of suspicious lesions, leading to timely intervention and improved patient outcomes. Moreover, the integration of OCT into routine clinical practice has the potential to reduce the burden associated with invasive procedures and diagnostic delays, ultimately enhancing the quality of care for individuals at risk of oral cancer.
However, despite these potential benefits, several challenges remain. Currently, there is a lack of precise definition of OCT patterns specific to various oral lesions. This hinders the consistent interpretation of OCT images and limits its diagnostic utility. Additionally, the accurate alignment of OCT findings with histological analysis is essential for validation and clinical applicability. Yet, there is still a need for standardized protocols to ensure proper overlay of OCT images with corresponding histopathological features.
Furthermore, while computerized OCT analysis holds promise for enhancing diagnostic accuracy, existing methodologies may be prone to biases. These biases must be addressed to develop robust algorithms capable of reliably detecting early signs of oral cancer, trained on standardized techniques of comparison between OCT and histology.
Therefore, addressing these challenges through the standardization of OCT imaging protocols, the establishment of consistent OCT patterns, and the development of unbiased computerized analysis methods is imperative. Doing so will not only advance the clinical utility of OCT in oral cancer diagnosis but also improve patient outcomes by enabling earlier detection and intervention.
Aims and approach:
- Standardization of technique for OCT scans and biopsy of oral lesions:
- Objective: To standardize the biopsy acquisition technique for both OCT and histological analysis, ensuring a reliable correlation between imaging modalities.
- Approach: We will develop and implement a standardized biopsy acquisition protocol, optimizing tissue preservation and alignment with OCT imaging parameters. This may involve specialized instrumentation and procedural guidelines tailored to maximize diagnostic yield, focusing on standardization of site and dimension of optical and surgical sampling. Detailed protocols will be established for OCT imaging, ensuring consistent acquisition parameters across all sites. Similarly, histological processing of biopsy specimens will adhere to standardized protocols to maintain integrity and facilitate accurate correlation with OCT findings. A novel optical and histological procedure of Target biopsy will be performed and assessed.
- Standardization of OCT patterns of oral carcinogenesis:
- Objective: To establish standardized patterns for OCT imaging of OPMDs and OSCCs, enhancing diagnostic accuracy.
- Approach: The evaluation of OCT images will entail meticulous analysis to identify consistent patterns reflective of various oral lesions. By correlating these patterns with histological findings, we aim to develop a comprehensive reference guide for interpreting OCT images with precision and consistency.
- Creation of Image Dataset for the Development of Diagnostic Software:
- Objective: To collect a comprehensive repository of OCT images, facilitating the development of digital diagnostic tools.
- Approach: A robust dataset comprising OCT images and corresponding histological data will be meticulously curated. This dataset will serve as the foundation for training and validating machine learning algorithms aimed at developing sophisticated diagnostic software capable of detecting early signs of oral cancer with high sensitivity and specificity.
By pursuing these objectives, we aim to not only evaluate the efficacy of OCT in early oral cancer diagnosis but also contribute to the standardization of diagnostic methodologies and pave the way for the integration of advanced technologies into clinical practice.
- Conditions
- Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder, Oral Leukoplakia, Proliferative Verrucous Leukoplakia, Oral Lichen Planus, Oral Lichenoid Lesion
- Being tested
- OCT (Optical Coherence Tomography)
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck, Leukoplakia, Oral, Lichen Planus, Oral, Graft vs Host Disease, Keratosis, Actinic, Actinic cheilitis, Mouth Neoplasms, Mouth Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OCT (Optical Coherence Tomography)Device
OCT diagnosis in oral carcinogenesis
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase I: Standardization of Biopsy and OCT Imaging Techniques
In Phase I, the focus will be on developing and implementing standardized protocols for biopsy acquisition and OCT imaging. This phase aims to optimize tissue preservation, ensure alignment with OCT imaging parameters, and enhance diagnostic yield through the standardization of site and dimension of optical and surgical sampling. Detailed protocols will be established for both OCT imaging and histological processing of biopsy specimens, laying the foundation for reliable correlation between imaging modalities.
Measured: This outcome will be assessed during the first year of study period.
Phase II: Development of Standardized OCT Patterns, Creation of Comprehensive Image Repository, and Training Algorithms
A meticulous analysis of OCT images will be conducted to standardize patterns reflective of various oral lesions. These standardized OCT patterns will not only enhance diagnostic precision but will also serve as the foundation for training algorithms. Concurrently, a robust dataset comprising OCT images and corresponding histological data will be meticulously curated. This comprehensive repository will facilitate the training and validation of machine learning algorithms, aimed at developing sophisticated diagnostic software. By incorporating standardized OCT patterns into algorithm training, clinicians can benefit from automated assistance in interpreting OCT images, thereby improving diagnostic accuracy and efficiency in oral cancer detection. This integrated approach represents a significant advancement in diagnostic methodologies, providing clinicians with robust software tool for early detection and intervention, ultimately enhancing patient outcomes and clinical practice.
Measured: this outcome will be assessed during the second year of study period.
Phase III: Development and Large-Scale Validation of Diagnostic OCT Software
In Phase III, the focus shifts towards the development and validation of diagnostic software empowered by the standardized OCT patterns and the comprehensive image dataset. Leveraging machine learning algorithms trained on this dataset, sophisticated diagnostic software will be meticulously designed to detect early signs of oral cancer with high sensitivity and specificity. This software will enable clinicians to efficiently interpret OCT images, providing automated assistance in diagnosis. Furthermore, extensive validation on a large scale will be conducted to ensure the robustness and reliability of the software across diverse clinical settings. By empowering clinicians with this advanced digital tool, Phase III aims to revolutionize oral cancer diagnosis, ultimately leading to improved patient outcomes and the transformation of clinical practice on a global scale.
Measured: this outcome will be assessed during the third year of study period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2024
- Study start13 Mar 2024
- Primary completion1 Apr 2027 (estimated)
- Study completion1 Apr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral Squamous Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Palermo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vera Panzarella, University of Palermo
- Investigators
- Vera Panzarella, Principal investigator, University of Palermo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06321003
- Sponsor's protocol ID
- OCT01
- Acronym
- SYMILIS OCT
- Status last verified
- Mar 2025
- First submitted
- 13 Mar 2024
- Last updated
- 23 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No